Curaleaf Finalizes Acquisition of Germany's Four 20 Pharma

Curaleaf Holdings, Inc., a notable international cannabis product provider, has completed the acquisition of the remaining 45% stake in Four 20 Pharma GmbH. This move solidifies Curaleaf's control over the German medical cannabis producer and distributor, renowned for its EU-GMP and GDP licenses and high-quality products.

Four 20 Pharma has established a significant presence across Germany and select European markets, ensuring compliance and patient care. The acquisition enhances Curaleaf’s global supply chain, providing a seed-to-patient quality guarantee. This development is seen as a strategic move to expand patient access and research within the cannabis industry.

Boris Jordan, CEO of Curaleaf, emphasized the importance of the European market and the strategic role of Four 20 Pharma in their growth plans. The partnership aims to build on success in Germany, with plans for brand expansion into the UK and Poland, emphasizing quality and compliance.